Cassava Sciences (SAVA) said late Tuesday that it is reducing its workforce by ten employees, laying off 33% of its workforce in Q1, incurring one-time expenses of $400,000 for the reduction.
The clinical-stage company said it will reduce expenses by halting the planned biomarker analysis of additional plasma samples from previous mid-stage studies of its investigational potential treatments for central nervous system diseases including Alzheimer's disease.
The measures come after the company said a late-stage study of its drug simufilam as a potential treatment for Alzheimer's patients did not meet its endpoints.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。